Helomics and DiaGen AI Team Up to Identify New Cancer Targets and Develop Anticancer Peptides
Key Points
- Helomics and DiaGen AI will evaluate 15 anticancer peptides using Helomics' biobank of more than 70,000 primary tumor biopsies.
- Research uses patient-derived 3D spheroid models and ChemoFx data to identify peptide targets, starting in breast cancer including TNBC.
- The approximately $1.5 million deal includes reciprocal 9.9% equity stakes and plans to expand findings to other cancers and small-molecule candidates.
DataMeds AI subsidiary Helomics has entered into a research and development partnership with Canadian biotechnology company DiaGen AI to identify new cancer drug targets and advance potential peptide-based therapeutics, combining artificial intelligence (AI)-driven discovery with one of the industry’s largest primary tumor biobanks.
The collaboration will initially concentrate on evaluating 15 anticancer peptides (ACPs) identified through DiaGen’s AI-based discovery methodology. The candidates have already demonstrated in vitro activity in breast cancer cell lines, including triple-negative breast cancer (TNBC), and will now undergo further investigation using Helomics’ tumor specimens and preclinical testing capabilities.
Under the agreement, DiaGen will gain access to Helomics’ biobank, which contains more than 70,000 primary tumor biopsies collected over nearly 30 years. The repository includes more than 50,000 gynecologic cancer specimens and provides researchers with access to patient-derived material across a broad range of cancer indications.
The companies intend to use this resource to investigate the biological targets associated with DiaGen’s peptide candidates, evaluate their activity against primary tumor samples and determine whether the findings could support development programs beyond breast cancer.
A central component of the collaboration is Helomics’ ability to evaluate drug candidates using primary tumor material and proprietary laboratory technologies. Its capabilities include cell-painting methods and patient-derived three-dimensional (3D) spheroid models designed to retain characteristics of the original tumor microenvironment, including stromal components.
These models, together with associated drug-response information from Helomics’ ChemoFx® assay, are intended to provide a more representative testing environment for assessing therapeutic candidates than conventional cell-line screening alone.
The initial research will examine 15 cytotoxic peptides developed using a methodology published in Nature Communications and incorporated into DiaGen’s CYPRESS platform. According to the companies, earlier laboratory studies demonstrated activity against breast cancer cells, with the peptides showing at least 5.5 times lower toxicity toward normal human blood cells than cancer cells. Their precise mechanism of action, however, has not yet been established.
The research team will work to identify the peptides’ molecular targets and investigate their activity in primary breast cancer biopsies, including samples from patients with TNBC.
“Being able to access this robust primary tumor biobank and Helomics’ proprietary capabilities to identify new therapeutic targets and leverage our proprietary BLACKCOMB artificial intelligence chemical drug discovery platform to design the best candidates for human clinical development is a transformative opportunity for DiaGen,” says Mohit Pandey, PhD, Chief AI Officer at DiaGen AI.
Pandey added that access to diverse, high-dimensional biological data will be important for developing AI-based discovery models and generating new intellectual property in areas of significant unmet medical need.
Beyond the initial breast cancer program, the partners plan to investigate whether identified therapeutic targets and mechanisms could have applications in other malignancies represented in the Helomics Biobank.
Potential areas of investigation include gastrointestinal, brain, head and neck, genitourinary, liver, lung, ovarian and pancreatic cancers, as well as melanoma, mesothelioma, sarcomas and uterine cancer.
DiaGen will also use its BLACKCOMB AI platform to generate a library of small-molecule drug candidates informed by the target discovery findings. Helomics will conduct preclinical testing using cancer cell lines and primary tumor specimens to help evaluate and prioritize candidates for further development. The companies also plan to assess selected candidates in breast cancer animal models.
Intellectual property generated through the joint target discovery work will be jointly owned by Helomics and DiaGen. Following the research and validation stages, the companies expect to pursue pharmaceutical industry partnerships or establish a joint venture to support further development of promising drug targets and therapeutic candidates.
The agreement includes a reciprocal equity component. DataMeds will issue 630,000 common shares to DiaGen, representing approximately 9.9% of DataMeds’ common shares outstanding as of the agreement date. In return, DiaGen will issue DataMeds shares representing 9.9% of its fully diluted common equity.
DataMeds will also cover up to half of the computing expenses associated with the collaboration, primarily through its existing infrastructure and technology expenditures. DiaGen will fund the laboratory costs associated with experimental work as research milestones are achieved.
The companies estimate the overall value of the arrangement at approximately $1.5 million in cash and in-kind contributions through the completion of project milestones. The anticipated research objectives include identifying and validating a lead therapeutic candidate with animal proof-of-concept data in breast cancer, including TNBC, as well as in vitro proof of concept across as many as 13 additional cancer types.
“We are excited to have identified our first partner that begins the process of monetizing the unique resources in our lab and will help us unlock the tremendous value resident in one of the world’s largest curated biobanks while also allowing us to participate in the long-term value creation of biotechnology drug discovery,” says Gerald Commissiong, Interim Co-CEO of DataMeds AI.
Commissiong also pointed to the opportunity to expand Helomics’ relationships with practicing oncologists and grow its biobank through additional clinical partnerships, while creating new commercial opportunities around its diagnostic and drug discovery capabilities.
Please visit www.diagen.ai for more information.
Total Page Views: 7

















